

Award schedule
NHS National Pharmaceuticals - Lenalidomide

Offer reference number: CM/PHG/21/5638
01/09/2022 to 31/08/2023 (12 months) with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
Lenalidomide - 01/09/2022 to ALL REGION 31/08/2023 (12 months) Shared Award

Table with 2 columns: Supplier Name, Sun Pharma Uk

All the products listed below are Subject to QC

Table with 18 columns: NPC, Description, Pack, QA Risk Category, Offer Pack, Brand, EAN Code, Product Licence no. or date expected, List Price, Minimum order quantity, Price (to include patient enrolment via a digital\*\* PPP), Price (to include patient enrolment via a paper-based PPP), NHS Stores discount (%), Product(s) registered on PharmaQC?\*, Digital image of product loaded to Pharmaqc?\*, Is PPP approved by MHRA?, If PPP not yet approved by MHRA state expected date, PPP format - Select Digital\*\* /Paper/Both, Will your PPP be provided via the BGMA portal when available?

\*Products must be registered and artwork/ documents uploaded onto PharmaQC for an award to be made
\*\* A digital portal is a secure cloud based portal that allows electronic capture and approval of patient authorisation forms.

Additional information

Table with 2 columns: Delivery details, Tender contact details